Related Experiment Video
Updated: May 11, 2026
06:11
Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
Published on: May 17, 2024
Prolactin receptor gene polymorphisms are associated with gestational diabetes
Trang N Le1, Sarah H Elsea, Roberto Romero
1Department of Pediatrics, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia 23298, USA. tle@mcvh-vcu.edu
Genetic Testing and Molecular Biomarkers
|May 9, 2013
Summary
Genetic variations in the prolactin receptor (PRLR) gene are linked to gestational diabetes mellitus (GDM). Specific single nucleotide polymorphisms (SNPs) in the PRLR gene increase GDM risk in pregnant women.
Area of Science:
- Endocrinology
- Genetics
- Reproductive Medicine
Background:
- Human placental lactogen (hPL) regulates maternal β-cell function via the prolactin receptor (PRLR) during pregnancy.
- This interaction is crucial for maintaining glucose homeostasis and meeting increased metabolic demands.
Purpose of the Study:
- To investigate the association between genetic variations in the PRLR gene and the risk of developing gestational diabetes mellitus (GDM).
Main Methods:
- Genotyping of 8 single nucleotide polymorphisms (SNPs) in the PRLR gene.
- Analysis of DNA samples from 96 mothers with GDM and 96 unaffected controls.
Main Results:
- Two PRLR SNPs (rs10068521 and rs9292578) showed significant associations with GDM.
- Carrying minor alleles of these SNPs was linked to a 2.36-fold increased risk of GDM.
Conclusions:
- Single nucleotide polymorphisms (SNPs) in the 5' UTR and promoter regions of the PRLR gene are associated with an elevated risk of GDM.
- These findings suggest a genetic predisposition to GDM related to PRLR variations in a Chilean population.
Related Concept Videos
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...